Lacticaseibacillus rhamnosus

DB19282ApprovedInvestigationalOrganism Based Therapies

Lacticaseibacillus rhamnosus: Overview.

Mechanism: Pharmacologically active on Nuclear factor NF-kappa-B
Curator reviewed
First approval: Canada, 2001
Also known as: Lactobacillus casei rhamnosus whole · Lactobacillus casei subsp. rhamnosus whole · Lactobacillus rhamnosus · Lactobacillus rhamnosus (hansen, 1968) collins et al., 1989 · Lactobacillus rhamnosus whole

Resolves to

Compound

Clinical / RWD

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

31Clinical trialsPhase, status and sponsor resolved per trial

16Marketed productsAcross 3 countries and 10 labellers

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Lacticaseibacillus rhamnosus, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.